MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$187,298K
(-67.03%↓ Y/Y)
Accrued liabilities
$71,253K
(117.34%↑ Y/Y)
Proceeds from exercise of
common stock options
$3,112K
Stock-based compensation
expense
$35,371K
(-23.26%↓ Y/Y)
Inventory write-down
$11,051K
Amortization of right-of-use
assets
$1,053K
Accrued interest, net of
interest received on...
$925K
(-72.52%↓ Y/Y)
Amortization of debt issuance
costs and discount
$464K
(-42.50%↓ Y/Y)
Net cash provided by
investing activities
$34,195K
(-83.85%↓ Y/Y)
Net cash used in
operating activities
$23,329K
(117.16%↑ Y/Y)
Net cash provided by
financing activities
$3,112K
(-70.02%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$57K
Canceled cashflow
$153,103K
Canceled cashflow
$96,782K
Net increase in
cash, cash...
$60,693K
(-29.57%↓ Y/Y)
Purchases of marketable
securities
$148,850K
(-58.23%↓ Y/Y)
Purchases of property and
equipment
$4,253K
Net loss
-$57,939K
(49.84%↑ Y/Y)
Accounts payable
-$21,136K
(-275.82%↓ Y/Y)
Inventory
$11,462K
(-61.05%↓ Y/Y)
Trade receivables,
net
$4,955K
(-80.50%↓ Y/Y)
Prepaid expenses and
other assets
$1,225K
(-97.27%↓ Y/Y)
Other non-cash items,
net
$65K
(106.90%↑ Y/Y)
Back
Back
Cash Flow
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
source: myfinsight.com